Indivior
INDV
$39.99
+0.48%
Indivior Pharmaceuticals is a specialty pharmaceutical company singularly focused on developing and commercializing treatments for opioid use disorder (OUD), operating within the Drug Manufacturers - Specialty & Generic industry. The company is a market leader in the OUD treatment space, distinguished by its portfolio of buprenorphine-based medications, including the long-acting injectable Sublocade and the sublingual film Suboxone. The current investor narrative revolves around the company's strong revenue growth and return to profitability, as evidenced by its recent quarterly results, which are driving a significant recovery in its stock price after a period of volatility. Attention is also focused on the company's ability to sustain this momentum and expand its market share in the critical and growing field of addiction medicine.…
INDV
Indivior
$39.99
Investment Opinion: Should I buy INDV Today?
Rating: Hold. The core thesis is that INDV's spectacular operational turnaround and growth are compelling, but they are fully priced in at current levels, and the investment is overshadowed by significant balance sheet and liquidity risks that demand a margin of safety not currently present.
The Hold rating is supported by four key data points: 1) The forward PE of 10.45x appears reasonable if $4.65 EPS estimates are met, but it hinges on flawless execution. 2) Revenue growth is robust at 19.73% YoY, demonstrating commercial success. 3) Profitability metrics are stellar, with gross margins of 82.12% and a net margin of 28.77%. 4) Analyst sentiment is uniformly bullish, providing a near-term floor of support. However, these positives are counterbalanced by a negative D/E (-3.58), negative FCF (-$85.6M), and a technically overbought price at 99.5% of its high.
The two biggest risks that could invalidate a Hold thesis are 1) a failure to generate positive free cash flow in the coming quarters, exposing liquidity needs, and 2) a deceleration in Sublocade growth below market expectations, triggering multiple compression. This Hold would upgrade to a Buy if the stock corrects 15-20% from its peak (to the mid-$30s) providing a better risk/reward entry, or if the company reports consecutive quarters of positive operating cash flow. It would downgrade to a Sell if revenue growth decelerates below 10% YoY or if liquidity concerns escalate. On valuation, the stock is fairly valued to slightly overvalued relative to its own volatile history, trading at the high end of its recent PE band, implying the market expects the bullish narrative to continue uninterrupted.
Sign up to view all
INDV 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The operational story is undeniably strong, with revenue re-accelerating and margins expanding dramatically. However, the investment case is bifurcated: the income statement screams 'buy' while the cash flow statement and balance sheet whisper 'caution.' The stock's parabolic rise has left no room for error, fully discounting the bullish narrative. The stance would upgrade to bullish on evidence of sustained positive free cash flow generation and a resolution of the negative equity situation. It would turn bearish if the next quarterly report shows a reversal in the revenue growth trajectory or a widening of the cash flow deficit. For now, the prudent course is to await either a better price or clearer proof of financial sustainability.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Indivior's 12-month outlook, with a consensus price target around $51.99 and implied upside of +30.0% versus the current price.
Average Target
$51.99
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$32 - $52
Analyst target range
Analyst coverage for INDV is limited, with only 3 analysts providing estimates, which is typical for a mid-cap specialty pharma stock and can lead to higher volatility and less efficient price discovery. The consensus sentiment appears bullish, as evidenced by recent institutional ratings from firms like HC Wainwright, Piper Sandler, and Craig-Hallum, which have all maintained 'Buy' or 'Overweight' ratings throughout 2025 and into early 2026, indicating sustained positive analyst conviction. While specific price targets are not provided in the data, the high and low revenue estimates for the forward period are $1.51 billion and $1.40 billion, respectively, implying a relatively tight range of expectations and suggesting analysts have a firm, consensus view on the company's near-term revenue trajectory, which supports the stock's recent price strength.
Bulls vs Bears: INDV Investment Factors
The investment debate for Indivior is a classic clash between explosive fundamental momentum and precarious financial health. The bull case, currently supported by stronger near-term evidence, is powered by staggering revenue growth (19.73% YoY), a dramatic return to high-margin profitability (28.77% net margin), and unanimous analyst bullishness. However, the bear case presents severe counterpoints: the stock is trading at a technical peak after a 198% rally, its balance sheet shows negative equity (-3.58 D/E) and negative cash flow (-$85.6M TTM), and high short interest (5.31 ratio) looms. The single most important tension is whether the company's surging operational profits can sustainably repair its weak balance sheet and generate positive free cash flow before the current premium valuation (21.36x trailing PE) compresses. The resolution of this cash flow generation versus cash burn dynamic will determine if this is a sustainable growth story or a speculative momentum play due for a reckoning.
Bullish
- Explosive Revenue & Profit Growth: Q4 2025 revenue grew 19.73% YoY to $358M, with a clear sequential acceleration from Q1 ($266M). This top-line strength translated into a dramatic return to profitability, with net income of $103M and a net margin of 28.77%, up from a net loss in Q2 2024.
- Superior Gross Margins & Operating Leverage: Gross margins are exceptionally high at 82.12%, reflecting the premium, patent-protected nature of its OUD treatments. The company is demonstrating significant operating leverage, with operating income surging from $4M in Q3 2024 to $122M in Q4 2025 as revenue scales.
- Strong Analyst Conviction & Growth Outlook: All three covering analysts (HC Wainwright, Piper Sandler, Craig-Hallum) maintain 'Buy' or 'Overweight' ratings. The forward PE of 10.45x implies the market expects a near-doubling of earnings, supported by analyst consensus revenue estimates of $1.46B for the forward period.
- Parabolic Technical Momentum: The stock has gained 197.92% over the past year and is trading at 99.5% of its 52-week high ($41.665), demonstrating immense momentum. It has significantly outperformed the SPY by 177 percentage points over the last year, indicating strong relative strength and investor demand.
Bearish
- Extreme Overbought & Valuation Risk: Trading at 99.5% of its 52-week high after a 198% run, the stock is technically overextended. The trailing PE of 21.36x is at the high end of its own historical range, leaving little room for error and making it vulnerable to a sharp correction, especially with a high beta of 1.174.
- Weak Balance Sheet & Negative Cash Flow: The company has a negative debt-to-equity ratio of -3.58, indicating negative shareholder equity, and a concerning current ratio of 0.71 suggesting liquidity constraints. Despite net income, trailing twelve-month free cash flow is negative at -$85.6M, raising questions about the sustainability of its financial turnaround.
- High Short Interest & Limited Analyst Coverage: A short ratio of 5.31 indicates significant bearish sentiment and potential for a short squeeze or heightened volatility. With only 3 analysts providing coverage, price discovery is less efficient, and the stock is more susceptible to large swings on limited news.
- Revenue Concentration & Competitive Threats: The company's fortunes are heavily tied to its buprenorphine portfolio (Sublocade, Suboxone). Any competitive entry, generic challenge, or pricing pressure in this niche market could disproportionately impact revenue, which grew 19.73% YoY but remains concentrated.
INDV Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 197.92% gain over the past year, culminating in a close at $41.47 on June 24, 2026. This price sits at approximately 99.5% of its 52-week high of $41.665, indicating the stock is trading at its absolute peak, which reflects immense momentum but also raises concerns about potential overextension and vulnerability to a sharp pullback. Recent momentum remains robust, with the stock up 38.46% over the last three months and 10.50% over the past month, significantly outperforming the SPY, which gained 13.66% and declined -1.66% over the same periods, respectively. This strong short-term performance, coupled with a high beta of 1.174, suggests the stock is exhibiting aggressive momentum that is 17.4% more volatile than the broader market, a critical factor for risk assessment. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $41.665 and support far below near the 52-week low of $13.47. A decisive breakout above $41.665 could signal a continuation of the parabolic move, while a failure here may trigger a significant correction given the extreme overbought conditions; the stock's high beta further implies any market-wide downturn could precipitate a more severe decline in INDV.
Beta
1.15
1.15x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$15-$43
Price range past year
Annual Return
+159.5%
Cumulative gain past year
| Period | INDV Return | S&P 500 |
|---|---|---|
| 1m | +6.3% | +1.9% |
| 3m | +31.2% | +14.0% |
| 6m | +11.4% | +8.9% |
| 1y | +159.5% | +20.1% |
| ytd | +11.9% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INDV Fundamental Analysis
Revenue growth has been exceptionally strong, with Q4 2025 revenue reaching $358 million, representing a 19.73% year-over-year increase, and the sequential trend from Q1 ($266M) to Q4 shows consistent quarterly growth, indicating a powerful acceleration in the business. The company's primary growth driver is its Sublocade franchise, which is successfully transitioning patients from daily films to the monthly injection, driving both top-line expansion and improved pricing. Profitability has dramatically improved, with the company reporting net income of $103 million in Q4 2025, translating to a robust net margin of 28.77%, and gross margins remain stellar at 82.12%, reflecting the high-value, patent-protected nature of its specialty pharmaceutical products. This marks a stark turnaround from periods of net losses, such as Q2 2024, and demonstrates effective cost management and operating leverage as revenue scales. The balance sheet and cash flow present a mixed picture; while the company generated $103 million in net income for the quarter, trailing twelve-month free cash flow is negative at -$85.6 million, and the debt-to-equity ratio is a concerning -3.58, indicating negative shareholder equity. The current ratio of 0.71 suggests potential liquidity constraints, meaning the company's ability to fund growth internally from operating cash flow remains a point of scrutiny despite the impressive return to net profitability.
Quarterly Revenue
$358000000.0B
2025-12
Revenue YoY Growth
+0.19%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-85619260.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INDV Overvalued?
Given the company's positive net income of $103 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio stands at 21.36x, while the forward PE is significantly lower at 10.45x, indicating the market expects a substantial near-term doubling of earnings, which aligns with the observed strong quarterly profit growth. Compared to sector averages, the trailing PE of 21.36x is not directly provided, but the forward PE of 10.45x suggests the stock may be trading at a reasonable multiple if earnings estimates are met, though a precise industry comparison requires more specific peer data from the valuation inputs. Historically, the stock's own PE ratio has fluctuated wildly, from deeply negative values during loss-making periods to a recent high of 21.36x; trading near this higher end of its own historical band suggests the market is currently pricing in optimistic expectations for sustained profitability and growth, leaving little room for operational missteps.
PE
21.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -6x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced and center on balance sheet fragility and cash generation. Despite a $103M net income quarter, the company's debt-to-equity is negative at -3.58, and shareholder equity is underwater. The current ratio of 0.71 indicates potential difficulty meeting short-term obligations without external financing. Most critically, trailing twelve-month free cash flow remains negative at -$85.6M, meaning the celebrated profitability is not yet translating into cash for debt repayment or self-funded growth, creating a dependency on capital markets or continued perfect execution.
Market & Competitive Risks are elevated by the stock's extreme valuation and technical position. Trading at 99.5% of its 52-week high with a 21.36x trailing PE, the stock is priced for flawless execution, leaving it vulnerable to multiple compression on any disappointment. Its high beta of 1.174 means it is 17.4% more volatile than the market, amplifying downside in a broader sell-off. Competitively, the company's revenue is concentrated in buprenorphine-based OUD treatments, making it susceptible to new market entrants, generic competition for Suboxone, or regulatory changes affecting addiction treatment reimbursement.
Worst-Case Scenario involves a perfect storm where a quarterly earnings miss triggers a valuation de-rating, coinciding with a market downturn that is magnified by the stock's high beta. This could unravel the momentum trade, leading to aggressive selling from weak-handed investors and covering by the significant short interest (5.31 ratio), creating a violent downdraft. The realistic downside could see the stock retrace a substantial portion of its gains, potentially testing the $30 support level seen in March-April 2026 or, in a severe scenario, falling towards the 52-week low of $13.47. From the current price of $41.47, this represents a catastrophic loss of up to -67.5%, though a more probable adverse move in the next 12 months might be a -30% to -40% correction to the mid-$20s, aligning with previous drawdowns.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Negative shareholder equity (D/E: -3.58) and negative trailing free cash flow (-$85.6M) create liquidity and solvency concerns. 2) Valuation & Technical Risk: The stock is extremely overbought, trading at 99.5% of its 52-week high after a 198% run, making it vulnerable to a sharp correction, especially with a high beta of 1.174. 3) Operational Concentration Risk: Revenue is heavily dependent on the buprenorphine portfolio, exposing it to competitive, generic, or pricing pressures. 4) Sentiment Risk: High short interest (short ratio 5.31) and limited analyst coverage (3 analysts) can lead to exaggerated price swings on limited news.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (50% probability) sees the stock trading between $38 and $44, as it meets analyst EPS estimates of ~$4.65 and growth moderates. The Bull Case (30% probability) projects a range of $48 to $55, driven by earnings beats, positive cash flow, and continued market share gains. The Bear Case (20% probability) warns of a decline to $25-$32 if growth decelerates and financial weaknesses are exposed. The most likely outcome is the Base Case, which assumes the company executes well but the stock consolidates after its massive rally. The key assumption is that INDV can maintain its current growth trajectory without a major stumble.
INDV appears fairly valued to slightly overvalued based on a mixed set of metrics. The forward PE of 10.45x seems reasonable and implies strong earnings growth, but the trailing PE of 21.36x is at the high end of its own volatile historical range. The price-to-sales ratio of 3.62 is not excessive for a high-margin specialty pharma company. However, the extreme negative price-to-cash flow ratio (-166.11) highlights the core valuation concern: the market is valuing the income statement story while discounting the cash flow statement reality. Overall, the valuation is not a clear bargain and prices in continued perfect execution, leaving little margin for error.
INDV is a compelling but risky investment at its current price. For aggressive investors comfortable with high volatility, the strong growth story (19.73% YoY revenue increase) and profitability turnaround (28.77% net margin) are attractive. However, with the stock trading at 99.5% of its 52-week high after a 198% rally and burdened by a weak balance sheet (negative D/E of -3.58) and negative cash flow (-$85.6M TTM), the risk/reward is balanced at best. It could be a good buy on a significant pullback (15-20%) for those who believe the operational momentum will eventually repair the financials. Conservative investors should avoid it due to the elevated risks.
INDV is not suitable for short-term trading due to its high volatility (beta 1.174) and the binary nature of its upcoming catalysts (earnings reports). It is also not a classic long-term 'buy and hold' investment until it demonstrates an ability to generate sustainable positive free cash flow and strengthen its balance sheet. The most appropriate horizon is a medium-term holding period of 12-24 months, allowing time for the company to either validate its turnaround story (making it a long-term hold) or fail to address its financial flaws (prompting an exit). Investors should be prepared for significant price swings during this period and have a clear plan based on quarterly results.